Autoimmune Cytopenia and BcR Inhibitors
Autoimmune Cytopenia and BcR Inhibitors
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated with Chronic
 Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia
 Organization (FILO)
The investigators of the study propose a card of data collection, validated by the scientific
 council of the group FILO.

 The data to be collected are entered on an e-CRF made available to the investigators on a
 secure site.

 The main data collected are as follows

 -  anonymized demographic data

 -  Clinical and Biological Data of CLL at Diagnosis

 -  Previous treatments of LLC and CAI

 -  clinical and laboratory data at the time of initiation of BCRi treatment

 -  response to treatment with BCRi

 -  tolerance to BCRi treatment

 -  Progression under treatment with BCRi

 -  Recent news
Inclusion Criteria:

 -  Patient with CLL

 -  Active autoimmune cytopenia

 -  Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.

 Exclusion Criteria:

 -  Other lymphoid hemopathy B

 -  Absence of documentation of the autoimmunity of cytopenia